A B S T R A C T Compactin (ML-236B) and the related compound, mevinolin, are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase), the rate-controlling enzyme in cholesterol synthesis. Previous studies have shown that administration of compactin to cultured cells elicits a compensatory increase in the amount of HMG CoA reductase in the cells. A similar increase in HMG CoA reductase has been reported in livers of rats and mice that have been treated with compactin. In this study, we explore the mechanism for the mevinolinmediated increase in hepatic HMG CoA reductase in mice that have been fed a control diet and a 2% cholesterol diet. Administration of mevinolin to mice on a control diet produced a 6-to 10-fold increase in the amount of HMG CoA reductase in liver microsomes. When mice were fed the cholesterol-enriched diet, cholesterol accumulated in the liver and HMG CoA reductase declined by 90%. The administration of mevinolin to cholesterol-fed mice produced a three to eightfold increase in HMG CoA reductase. Despite the abundant amount of cholesterol that was already present in the livers of the mevinolin-treated, cholesterol-fed animals, their elevated HMG CoA reductase could be rapidly suppressed by the subcutaneous injection of small amounts of mevalonate, the product of HMG CoA reductase. These data are compatible with the existence in mouse liver of a multivalent feedback regulatory mechanism for HMG CoA reductase in which suppression of the enzyme requires both a sterol and a nonsterol substance derived from mevalonate. By blocking mevalonate synthesis, mevinolin activates this regulatory mechanism, and this in turn causes an increase in hepatic HMG CoA reductase. The ability to suppress the elevated HMG Dr. Toru Kita is the recipient of a travel grant from the Japan Research Foundation for Clinical Pharmacology.
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INTRODUCTION
The discovery by Endo et al. (1) of compactin (ML 236-B), a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase),' the rate-controlling enzyme in cholesterol synthesis, has important implications for the therapy of hypercholesterolemia in man (2) . Compactin, which was originally isolated from Penicillium brevicompactum (3) , is a potent inhibitor of cholesterol synthesis in intact animals (1, 4) and in cultured cells (5) (6) (7) . Recently, a related fungal metabolite, called monacolin K (8) or mevinolin (9) , has been isolated from different fungal strains. Alberts et al. (9) demonstrated that the structure of mevinolin resembles that of compactin except for the presence of one additional methyl group. These workers also showed that mevinolin is even more potent than compactin in its ability to inhibit HMG CoA reductase activity.
An unexpected action of compactin, which was first noted in cultured human fibroblasts, is its ability to cause the accumulation of large amounts of HMG CoA reductase enzyme in the cell (5) . Accumulation of the enzyme occurs in response to a regulatory mechanism that is triggered when compactin inhibits HMG CoA reductase and thereby deprives the cells ofmevalonate, the product ofthe enzyme. The induced HMG CoA reductase is not active in the cell because it is inhibited by compactin. However, its activity can be measured in cell-free extracts in which the compactin-mediated inhibition is overcome by dilution (5). The high levels of HMG CoA reductase are suppressed partially when the cells are given exogenous cholesterol, the major end product of mevalonate metabolism. Full suppression of HMG CoA reductase occurs only when the cells are given small amounts of mevalonate in addition to exogenous cholesterol (5, 10) . These findings have led to the hypothesis that HMG CoA reductase is normally regulated in cultured cells by a multivalent process in which full suppression of the enzyme requires both cholesterol and one or more nonsterol products derived from mevalonate (5, 10) . By inhibiting mevalonate synthesis, compactin activates this regulatory mechanism and causes HMG CoA reductase levels to rise.
Subsequent studies have demonstrated an increase in HMG CoA reductase in the livers of mice and rats that have been treated with oral compactin (11) . This increase in HMG CoA reductase is of practical concern because it creates a resistance to the effectiveness of compactin in inhibiting cholesterol synthesis (11) . Inasmuch as compactin is a competitive inhibitor of the enzyme, a given level ofcompactin inhibits the enzyme by a fixed percentage. As the amount of HMG CoA reductase increases, an increasing percentage of inhibition is required to reduce cholesterol synthesis to a given absolute value (5-7).
It is important to determine whether the mechanism for the compactin-mediated increase in HMG CoA reductase in rodent liver is similar to that proposed for cultured cells. If To prepare the 2% cholesterol diet, 20 g of cholesterol was dissolved in 400 ml of warm (55°C) ethanol, and the solution was mixed with 1 kg of powdered formula chow, after which the ethanol was removed by evaporation. The control diet consisted of powdered formula chow.
For administration to animals, 90 mg of mevinolin in the lactone form was dissolved in 1.8 ml of warm (55°C) ethanol, after which 0.9 ml of 0.6 N NaOH and 18 ml of water were added. The solution was incubated at room temperature for about 30 min to complete the conversion of mevinolin to the sodium salt. The final mevinolin solution (4 mg/ml) was adjusted to pH 8.0 with HCI and the volume was brought to 22.5 ml. This mevinolin solution was stored in multiple aliquots at -20°C until use. Control animals received a solution prepared in the same way except that mevinolin was omitted (solution A). Mevalonolactone (100 mg/ml) was dissolved in 10 mM potassium phosphate (pH 4.5) and stored in multiple aliquots at -200 until use.
Preparation of liver microsomes. Mice were killed by decapitation between 1 and 2 p.m., the livers were immediately removed, and equal pieces of livers from three animals (-0.5 g/liver) were pooled. All subsequent operations were carried out at 40C unless otherwise indicated. Each group of pooled livers (1.5 g) was homogenized in 6 ml of ice-cold solution containing 0.3 M sucrose, 10 mM t3-mercaptoethanol, and 10 mM sodium EDTA (pH 7.4). The livers were homogenized with 10 strokes of a loose Dounce pestle followed by 5 strokes of a tight pestle. Aliquots were removed for measurement of free and esterified cholesterol content. Each homogenate was then centrifuged for 15 min at 12,000 g, and the supematant fraction was again centrifuged for 15 min at 12,000 g.The resulting supemate was centrifuged for 60 min at 100,000 g. Each pellet was resuspended in 4 ml of solution containing 0.3 M sucrose and 10 mM t3-mercaptoethanol, and this suspension was again centrifuged for 60 min at 100,000 g. Unless otherwise indicated, the resulting microsomal pellets were frozen immediately in liquid nitrogen and were stored at -800C. Before assay of HMG-CoA reductase activity, each pellet (3.4-18 mg of protein) was resuspended in 1-6 ml of buffer A (20 mM imidazolechloride [pH 7.4] and 5 mM dithiothreitol).
Standard assay of microsomal HMG CoA reductase. The standard assay for HMG CoA reductase activity consisted of two sequential steps as previously described (12) (13), with bovine serum albumin as a standard. The content of free and esterified cholesterol in whole homogenates of liver was measured by gas-liquid chromatography as previously described (14) .
RESULTS
Subcutaneous administration of mevinolin to mice at a dose of 33-40 mg/kg body wt every 12 h produced an increase in hepatic HMG CoA reductase activity that remained high throughout the 12-h interval between doses. 28 h after the initiation ofthis treatment schedule, the HMG CoA reductase activity in control mice was elevated by > 10-fold (open circle at zero time in Fig. 1 Fig. 1 ). In the cholesterol-fed mice, mevinolin raised the HMG CoA reductase activity from an average of 15 to -125 pmol/ min per mg protein, an increase of eightfold.
Despite the large differences in the absolute levels of HMG CoA reductase activity among the various treatment groups in Fig. 1 , a range of protein concentrations could be found in each case in which the HMG CoA reductase assay was linear with increasing amounts of added microsomes (Fig. 2) . Under these conditions, the assay was also linear with time up to at least 90 min (data not shown). The enzyme concentration curves in Fig. 2 also illustrate the increase in HMG CoA reductase activity produced by mevinolin in control animals ( Fig. 2A) and in animals fed a 2% cholesterol diet (Fig. 2B) .
Hepatic HMG CoA reductase exists in two interconvertible forms (12, (15) (16) (17) . In its phosphorylated form, the enzyme is inactive, whereas in the nonphosphorylated form it is active (15-17). Homogeniza- FIGURE 1 Mevinolin-mediated enhancement of HMG CoA reductase activity in the livers ofcholesterol-fed mice. Groups of mice (three mice per group) were fed a 2% cholesterol diet for the indicated time. The onset ofthe diet was staggered in such a way that all animals could be killed at the same time after having consumed the diet for variable periods as indicated. At the designated time after beginning the cholesterol diet (arrow), groups of animals were injected subcutaneously with 1 mg of mevinolin (0). The injections were repeated twice at 12-h intervals (total of three injections). Control groups of animals were injected subcutaneously with solution A (three injections at 12-h intervals (c). All the animals were killed on the same day at 1 p.m., 4 h after the last injection of mevinolin. The livers from the three mice in each group were pooled for homogenization. Microsomes were prepared, treated with alkaline phosphatase, and assayed for HMG CoA reductase activity as described under Methods. tion of the liver in the presence of sodium fluoride prevents the dephosphorylation that normally occurs when the liver is homogenized (15) and is thus felt to preserve the relative proportions of active and inactive enzymes that were present originally in the tissue (12, 15) . Treatment of the isolated microsomes with E. coli alkaline phosphatase removes the phosphate group from the enzyme and permits an estimate of the total amount of enzyme (active plus inactive) in the tissue (15) . In the preceding experiments, the homogenates were prepared in the absence of fluoride, and the microsomes were treated with alkaline phosphatase before assay to measure the total amount of hepatic HMG CoA reductase. To estimate the proportion of reductase that was in the active form, we performed an experiment in which the animals were placed on a control or 2% cholesterol diet and then treated with or without mevinolin (Table I) . Livers from animals in each of the four groups were then homogenized in the absence or presence of sodium fluoride, and portions of the microsomes were assayed either without prior incubation or after prior incubation with alkaline phosphatase to activate the phosphorylated enzyme. In the control animals, the activity of HMG CoA reductase in the fluoride-treated microsomes was low and was stimulated sevenfold by treatment with alkaline phosphatase. This degree of enhancement is similar to the one previously observed in rat liver (12, 15) . When the animals were treated with mevinolin, the total HMG CoA reductase activity rose by -6.5-fold, and the relative stimulation by alkaline phosphatase in the fluoride-treated microsomes did not change significantly. When the mice were fed cholesterol, the total reductase activity declined by -85%. The fluoride-treated enzyme was stimulated -twofold by alkaline phosphatase treatment, suggesting that a proportion of enzyme was still in the inactive form in the tissue. Administration ofmevinolin to the cholesterol-fed mice increased the total HMG CoA reductase activity threefold, from 18 to 51 pmol/ min per mg protein. Again, the degree of stimulation of the fluoride-treated microsomes by alkaline phosphatase was not changed by mevinolin. Edwards et al. (18) have shown that administration of large amounts of mevalonate orally to rats produces a prompt decline in hepatic HMG CoA reductase activity, apparently because the mevalonate is converted to sterols and perhaps other products that suppress the activity of the enzyme. In mice, the elevated HMG CoA reductase activity that was elicited by mevinolin was also rapidly suppressed when the animals were given mevalonate subcutaneously (Fig.  3) . In mice on a control diet plus mevinolin (Fig. 3A) , the activity of HMG CoA reductase was high and was suppressed by -90% within 2 h after the subcutaneous injection of 10 mg of mevalonate in the lactone form. When the animals had been fed a high cholesterol diet, and HMG CoA reductase activity had been elevated by mevinolin (Fig. 3B) , the administration of mevalonolactone also produced a rapid decline in hepatic HMG CoA reductase (Fig. 3B) .
The dose-response curve for mevalonate was different in the control and cholesterol-fed animals treated with mevinolin (Fig. 4) . In the mevinolin-treated animals on a control diet, the administration of small amounts of mevalonolactone (<1 mg/mouse) led to a paradoxical twofold increase in HMG CoA reductase activity as measured 3 cholesterol-fed mice. Five groups of mice (three mice per group) were fed either a control diet (A) or a 2% cholesterol diet (B) for 53 h. 23 h after beginning the diet, the mice in both diet groups were injected subcutaneously with 1 mg of mevinolin. The injections were repeated twice at 12-h intervals (total of three injections). At the indicated time before killing, the animals in each group received one subcutaneous injection of 10 mg of mevalonolactone. All mice were killed at 2 p.m., 6 h after the last dose of mevinolin. The livers from the three mice in each group were pooled for homogenization. Microsomes were treated with alkaline phosphatase and assayed for HMG CoA reductase activity as described under Methods. Six mice were fed either a control diet or a 2% cholesterol diet for 124 h as indicated. 96 h after beginning the diet, mice in both diet groups were injected subcutaneously with 1 mg of mevinolin. The injections were repeated twice at 12-h intervals (total of three injections). 2 h after the last dose of mevinolin, groups of three control mice and three cholesterol-fed mice received one subcutaneous injection of0.3 ml of 10 mM potassium phosphate (pH 4.5) with or without 30 mg of mevalonolactone. All mice were killed at 1 p.m., 2 h after injection of mevalonolactone or the control solution. The livers from the mice in each treatment group were pooled for homogenization and microsomes were prepared in the absence or presence of sodium fluoride as described in the legend to Table I . HMG CoA reductase was assayed after prior incubation in the absence or presence of 5 U ofalkaline phosphatase as described in the legend to (10) . The fibroblast experiments have been interpreted to indicate the existence of a multivalent feedback mechanism in which cholesterol and a nonsterol product derived from mevalonate are both required for maximal suppression of HMG CoA reductase activity. By inhibiting the synthesis of mevalonate, compactin blocks the synthesis of both regulators and thus produces a compensatory increase in HMG CoA reductase that is reversed only when the cells can synthesize or take up sufficient amounts of both substances (5, 10) . The current study demonstrates that a similar increase of HMG CoA reductase occurs in livers of cholesterol-fed mice given mevinolin. Although these results are compatible with the existence of a multivalent feedback mechanism in mouse liver, further studies will be necessary to deduce the details of the system and to identify the putative nonsterol feedback regulator.
The current in vivo experiments were designed primarily to measure changes in the total amount of HMG CoA reductase (active plus inactive forms) in mouse liver. To this end, we adopted a procedure previously established for rat liver (12) in which the microsomes were treated with E. coli alkaline phosphatase before assay to convert any phosphorylated inactive enzyme to the dephosphorylated active form. Neither mevinolin nor mevalonate affected the proportion of enzyme in the active form, as determined by alkaline phosphatase activation of microsomes prepared in the presence of sodium fluoride. Thus, the increase in total HMG CoA reductase elicited by mevinolin appears to represent an increase in the total number of HMG CoA reductase molecules. Such an increase might be produced theoretically by an enhanced rate of enzyme synthesis, a decreased rate of enzyme degradation, or both. Similarly, the suppression ofthe induced enzyme by mevalonate might be due either to inhibition of synthesis, to stimulation of degradation, or to both. Further experiments will be necessary to make this distinction. If, as suggested by the current study, a multivalent feedback mechanism for HMG CoA reductase exists in liver, and if prevention of the mevinolin-mediated increase in HMG CoA reductase requires both cholesterol and a nonsterol product derived from mevalonate, the current findings may have relevance to the use of mevinolin and related compounds for the control of hypercholesterolemia in man. On the basis of the current data, we suggest that the rise in hepatic HMG CoA reductase observed after treatment with mevinolin and compactin may be prevented by the simultaneous administration of mevalonate or, preferably, the nonsterol substance derived from mevalonate that participates along with cholesterol in the suppression of HMG CoA reductase. Efforts to identify this putative nonsterol molecule are currently underway.
